Browse the evidence

The FDA has conditionally approved Resmetirom as the first pharmacological treatment for MASH.

Clinicians should consider Resmetirom as a treatment option for MASH.

Recent innovations in bariatric research include pharmacological therapies targeting GLP-1 receptors, minimally invasive procedures, and genetic and microbiome-based strategies.

These innovations may provide new options for obesity treatment.

Pharmacoeconomic analyses support the cost-effectiveness of combining behavioral, pharmacological, and surgical modalities for obesity treatment.

Integrating various treatment modalities can enhance cost-effectiveness in obesity management.

Obesity management requires understanding both genetic and environmental components.

Practitioners should consider both genetic and lifestyle factors in obesity treatment.

Lifestyle interventions can help in the prevention and treatment of obesity by altering epigenetic signatures.

Encouraging lifestyle changes can be an effective strategy in obesity treatment.

At average weight loss, the effect of a higher PS amounted to a change of 0.20-0.28 cm per standard deviation in WCadjBMI.

The small effect size suggests that genetic factors may have limited practical implications for weight loss interventions.

Plant-based diets improve cardiovascular health by modulating gut microbiota and metabolites.

Practitioners may consider recommending plant-based diets for cardiovascular health.

Early genetic diagnostics can identify the type of obesity and guide therapy options.

Implementing genetic testing can enhance personalized treatment strategies for obesity.

GLP-1 receptor agonists and dual incretin agonists provide clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.

Practitioners can consider GLP-1 receptor agonists and dual agonists as effective options for managing weight and cardiovascular health in patients with T2DM and obesity.

Consumption of ultra-processed foods (UPFs) is associated with increased cardiovascular (CV) risk.

Clinicians should consider the impact of UPFs when advising patients on cardiovascular health.

Modified probiotic strains and supraphysiological dosages of microbial metabolites may be beneficial in combatting obesity.

Consider using modified probiotics and microbial metabolites in obesity treatment strategies.

Ultra-processed foods (UPFs) may be associated with obesity and asthma.

Reducing UPF consumption may benefit individuals at risk for obesity and asthma.

Obesity and diabetes mellitus are major risk factors for the development and progression of chronic kidney disease (CKD).

Healthcare providers should prioritize screening for CKD in patients with obesity and diabetes.

Caloric restriction-induced transcriptional reprogramming in adipose tissue implicated pathways regulating mitochondrial bioenergetics, anti-inflammatory responses, and longevity.

Caloric restriction may promote metabolic health through specific molecular pathways.

Reduction of PLA2G7 may mediate the immunometabolic effects of caloric restriction and could potentially lower inflammation and extend health span.

Targeting PLA2G7 may be a strategy to reduce inflammation and improve health span.

SCD1 is a key enzyme that regulates energy homeostasis and various physiological processes.

Understanding SCD1's role can help in targeting metabolic diseases.

Aberrant activation of SCD1 contributes to obesity, non-alcoholic fatty liver, diabetes, and cancer.

Targeting SCD1 may help in managing these metabolic diseases.

Insulin sensitizers such as PPARγ (pioglitazone) and pan-PPARs agonists (lanifibranor) have shown beneficial effects on both NASH and liver fibrosis.

Consider insulin sensitizers as part of the treatment plan for NASH and liver fibrosis.

ω-3-PL/FFA was well tolerated with a safety profile similar to that of placebo.

Practitioners can confidently recommend ω-3-PL/FFA as a safe option for patients.

The study of exercise as a preventative or therapeutic treatment is increasingly interdisciplinary and impactful.

Researchers and practitioners should collaborate across disciplines to enhance exercise interventions.

MYOD1, MYF5, and MYF6 mean methylation was reduced after 4 and 8 hours in response to all exercise protocols.

Resistance, high-intensity interval, and concurrent exercise can effectively reduce DNA methylation in myogenic regulatory factors.

Changes in DNA methylation and mRNA expression were largely confined to the late (4-8 h) recovery period.

Recovery periods after exercise are critical for observing changes in muscle regulatory factors.

Semaglutide has a higher pooled reporting odds ratio (ROR) for gastrointestinal adverse drug reactions (GADRs) compared to liraglutide (5.53 vs 3.95).

Clinicians should consider the higher gastrointestinal risk associated with semaglutide when prescribing.

Semaglutide has a later pooled time-to-onset median of GADRs compared to liraglutide (7 days vs 4 days).

Healthcare providers should be aware of the delayed onset of gastrointestinal issues with semaglutide.